ZLB Plasma Re-Brands Its Name to CSL Plasma

ZLB Plasma has changed its name to CSL Plasma to align more closely with its parent company, CSL Limited. CSL Plasma is one of the world's largest collectors of human plasma for use in manufacturing life-saving biotherapies.

Headquartered in Boca Raton, FL, CSL Plasma operates collection centers throughout the United States and in Germany. It also operates state-of-the-art testing laboratories in Knoxville, TN and Goettingen, Germany, and logistics centers in Indianapolis, IN and Schwalmstadt, Germany.

Employees of CSL Plasma adhere to the highest standards of quality and safety in collecting plasma because peoples' lives depend on it. The plasma collected by CSL Plasma enables tens of thousands of people who use plasma-derived biotherapies to live normal, healthy lives.

Plasma is the essential ingredient in manufacturing products crucial to treating a variety of life-threatening medical conditions. Plasma donors must be 18 years of age or older, weigh at least 110 pounds, be in good health and meet proper identification and residency requirements. To learn more about donating plasma or to locate a center, visit www.cslplasma.com.



CSL Plasma is a division of CSL Behring, a plasma protein biotherapies company, headquartered in King of Prussia, PA. CSL Behring is committed to saving lives and improving the quality of life for people with rare and serious diseases worldwide. The company traces its corporate roots to the founding of Behringwerke, established in 1904 by Emil von Behring, the first recipient of the Nobel Prize for Medicine and Physiology.

CSL Behring manufactures and markets biotherapies indicated for the treatment of coagulation or bleeding disorders, such as hemophilia and von Willebrand disease; immune deficiencies; and Alpha1 deficiency. Biotherapies are also used to treat clotting during cardiac surgery, cytomegalovirus (CMV) following organ transplantation and hemolytic disease in newborns. Additionally, biotherapies are used in critical care settings to promote wound healing and to treat shock, burns and sepsis.

CSL is focused on innovation through new product development, market development and life-cycle management of plasma-derived or recombinant products, vaccines, and biopharmaceuticals. CSL currently employs more than 10,000 employees in 27 countries.

For more information, visit www.cslplasma.com